SCHEMBL3638754

SCHEMBL3638754

Clc1ccc(NCc2c[nH]nc2-c2cccs2)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.39
NR1H4 Q96RI1 1/20 0.38
ALDH1A1 P00352 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.38
HPGD P15428 1/20 0.38
PGK1 P00558 1/20 0.36
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
PKM P14618 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640108 0.91 LMNA (0.42) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3635672 0.87 MAPT (0.39) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3637346 0.84 KMT2A (0.42) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3638148 0.82 KDM4E (0.47) KMT2ANR1H4ALDH1A1HPGDMAPT
SCHEMBL3638176 0.82 MAPT (0.43) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3638150 0.82 ALDH1A1 (0.42) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3635764 0.80 MAPT (0.44) KMT2ALMNAALDH1A1SMN1; SMN2PGK1
SCHEMBL3633954 0.79 MAPT (0.45) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3638003 0.77 ADRA2C (0.46) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2
SCHEMBL3636396 0.77 L3MBTL1 (0.43) KMT2ALMNANR1H4ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 KMT2A 595/4885LMNA 4827/4885MRGPRX4 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.